Capsular Contracture After Breast Implants: A Practical Revision Guide

A capsule is part of normal healing around any implanted device. In an uncomplicated augmentation, it is thin and flexible enough to move with the implant and surrounding breast. Capsular contracture is the pathologic end of that response: the capsule thickens, shortens, or tightens around the implant. The implant may feel less mobile, sit higher, look rounder, or become compressed into an unnatural shape.

Contracture can affect one breast or both, and the two sides do not have to progress at the same rate. It may appear within months of surgery or emerge gradually years later. A late change should not be dismissed as normal aging of the implant. Rupture, implant displacement, fluid around the implant, infection, and other breast conditions can produce overlapping symptoms, so a new change needs examination rather than self-diagnosis.

Capsular contracture is also not synonymous with having a capsule. Everyone with an implant forms a capsule. Removing every normal capsule would expose patients to additional dissection without a corresponding clinical reason. The relevant questions are whether the capsule is causing symptoms, whether it is abnormal on examination or imaging, and whether another implant-related problem is present.

The first change many patients notice is firmness. One breast may no longer spread naturally when lying down, or it may feel tighter than the other. As contracture progresses, the implant can appear higher or more spherical, the lower breast contour can shorten, and visible asymmetry can develop. Tightness, pulling, tenderness, or pain are more concerning when they accompany a change in shape.

Clinicians commonly describe these capsular contracture symptoms with the Baker classification. It is a physical-examination scale, not a laboratory test. The border between grades can be subjective, and prior reconstruction or very thin tissue can make grading less straightforward. Ultrasound and the rest of the clinical assessment help determine whether firmness is truly contracture and whether rupture, fluid, or a position problem also needs attention.

• •A breast that has become harder than it used to be, especially on one side.
• •An implant that stays round and upright instead of settling naturally when lying down.
• •A higher implant position, shortened lower pole, or a new change in breast shape.
• •Tightness, squeezing, pulling, tenderness, or pain.
• •A change that begins months or years after an initially stable result.

There is rarely one provable cause in an individual patient. Current clinical thinking treats capsular contracture as a final pathway that can be influenced by inflammation, blood around the implant, bacterial contamination and biofilm, implant position, surface behavior, and the patient’s own scar response. Two people can undergo apparently similar operations and heal differently. For that reason, a risk factor should not be presented as a certain cause, and the absence of an identified factor does not make future contracture impossible.

Bleeding is one plausible pathway. A hematoma leaves blood products in the pocket and can amplify inflammation while the capsule is forming. A 2025 retrospective study of 212 patients, covering 386 implants, found an association between observed hematoma and contracture with an odds ratio of 14.60. Its 95% confidence interval was very wide, from 1.78 to 118.90. This was an observational, small-sample estimate: it supports an association, not proof that hematoma caused contracture or a precise multiplier for an individual patient.

Low-level bacterial contamination is another proposed contributor. Bacteria may adhere to the implant or capsule as a biofilm without producing the dramatic signs of an acute infection. The theory helps explain why careful skin preparation, controlled implant handling, and a no-touch protocol are used, but it does not mean that every contracture is an infection or that a no-touch technique can eliminate the complication.

Late contracture can also coexist with implant rupture or chronic inflammation. That is why a breast becoming newly firm after years of stability deserves imaging. Treating the firmness without looking for the underlying problem can miss information that changes the revision plan.

Risk is shaped by the operation, the implant environment, and individual healing biology. Pocket placement is one measurable factor, although placement must never be selected from a contracture statistic alone. In the ten-year Natrelle round core study, reported contracture rates within that study were 15.7% for submuscular placement and 26.3% for subglandular placement. A 2025 meta-analysis of 24 studies reported lower odds with submuscular placement, with an odds ratio of 0.35 and a 95% confidence interval of 0.25 to 0.50. The included studies and patient groups varied, and these data do not prove that one plane is right for every anatomy.

A plane also affects animation, soft-tissue coverage, implant visibility, and the shape of the breast. A thin patient may benefit from additional coverage; another patient may have anatomy or priorities that support a different plane. The decision should balance the entire breast, not optimize one complication in isolation.

Other risk considerations include a postoperative hematoma, repeated inflammation, a complicated revision pocket, and a personal tendency toward a strong fibrotic response. Previous contracture is important history because revision starts in tissue that has already shown abnormal capsule behavior. None of these points predicts an inevitable recurrence. They identify where diagnosis, operative planning, and follow-up need to be especially deliberate.

Published incidence also depends on how contracture was defined, which Baker grades counted, whether surgery was augmentation or reconstruction, implant generation, placement plane, and follow-up completeness. A headline percentage should therefore be read as a result in a defined study population, not a personal forecast.

Smooth, macro-textured, and nano-surface implants interact differently with tissue. Because studies vary in design and follow-up, the table describes trends rather than a product ranking.

For context, separate manufacturer core studies reported ten-year cumulative Baker III or IV contracture rates of 12.1% in 552 primary-augmentation patients with Mentor MemoryGel and 18.9% in 455 primary-augmentation patients with Natrelle round implants. These are results from different approval studies, with different designs and follow-up; they are not a head-to-head comparison and cannot be used to rank products or represent Umnagumo’s results.

Spontaneous adverse-event reporting systems can help detect a possible safety signal, but they do not provide a reliable denominator, may contain duplicate or incomplete reports, and cannot establish incidence or causation. More reports do not automatically prove that one device causes more events, and the absence of a detected report or signal does not establish that a device is safe. Implant choice requires the total evidence, current regulatory information, anatomy, and the patient’s priorities.

No prevention protocol can reduce risk to zero. Prevention is a chain of small, controlled decisions before, during, and after surgery. The surgeon first plans a pocket that matches the implant footprint and the patient’s chest-wall geometry. A pocket that is precise rather than excessively wide or traumatized limits unnecessary dissection, helps keep the implant stable, and makes meticulous bleeding control easier.

Hemostasis matters because retained blood and hematoma are associated with later contracture. During dissection, bleeding points are controlled and the pocket is checked before the implant is inserted. This does not turn an observational association into a guarantee, but it addresses a biologically plausible and surgically modifiable factor.

A no-touch protocol aims to reduce contact between the implant and skin, gloves, or surfaces as it enters the pocket. It typically works alongside skin preparation, controlled handling, and irrigation practices selected by the operating team. Its role is risk reduction, not proof that contamination is the sole cause of contracture. A technically careful operation can still be followed by contracture because healing biology cannot be fully controlled.

After surgery, follow the implant- and surgeon-specific instructions rather than a generic massage video. Massage recommendations differ by implant surface and pocket strategy. Forceful massage does not reverse an established, thick contracture and may place stress on the capsule or implant. Scheduled review is more useful than trying to grade a changing breast at home, particularly when one side becomes progressively firmer or painful.

• •Pocket precision matched to chest-wall anatomy and implant dimensions.
• •Minimal tissue trauma and meticulous control of bleeding.
• •A consistent no-touch protocol and controlled implant handling.
• •Surface- and procedure-specific postoperative instructions.
• •Prompt assessment of unusual swelling, increasing pain, redness, fever, or a late change in shape.

Diagnosis starts with the timeline. The clinician asks when firmness began, whether it is progressing, whether pain or swelling is present, and whether the breast was previously stable. Prior operative records are useful: implant model and surface, size, placement plane, incision, previous contracture, and any earlier revision can all change the differential diagnosis and surgical map.

Examination compares softness, implant mobility, breast shape, fold position, and pain on both sides. The clinician assigns a Baker grade when that scale fits the presentation, but the grade is not the entire diagnosis. Grade III describes visible distortion and Grade IV adds pain; neither explains by itself why the change happened.

Ultrasound helps assess the implant, the apparent capsule, surrounding fluid, and other structural causes of asymmetry. It can help identify a suspected rupture or fluid collection that requires a different work-up. Imaging is interpreted together with examination; a scan that does not detect a problem is not a guarantee of future safety, and persistent or changing symptoms may require further evaluation.

Seek timely clinical review for rapid swelling, redness, warmth, fever, drainage, marked new pain, or a sudden late enlargement. These findings are not the usual definition of uncomplicated contracture and may point to infection, bleeding, fluid, or another implant-related condition.

The word capsule can sound uniform on a scan or consent form, but operative findings vary. A normal capsule may be thin, clean, and pliable. A contracted capsule may be dense and tight across the whole pocket or concentrated in one region, pulling the implant upward or narrowing the lower pole. Some capsules are thick but separable; others are firmly adherent to the muscle or chest wall. Calcification can create hard plaques. If silicone rupture is present, gel may be contained within the capsule or infiltrate capsule tissue.

These differences determine what can be removed safely. A thick anterior segment may separate cleanly while a very thin posterior layer is fused to the ribs or intercostal tissues. Pursuing that layer at any cost can increase bleeding, tissue injury, or chest-wall risk. In another patient, the capsule may come away intact and total removal may be reasonable. This is why a responsible plan describes intended options and trade-offs rather than promising a particular capsule specimen before surgery.

The pocket itself is also inspected. The surgeon looks for residual blood products, chronic fluid, implant damage, abnormal fold position, tissue thinning, and whether the old plane should be maintained or changed. Removed capsule or fluid may be sent for pathologic or other indicated testing when the history and findings warrant it. The goal is to treat the actual problem found, not to make the most aggressive dissection the default.

Treatment is matched to symptoms, Baker grade, imaging, implant condition, tissue quality, and the patient’s goals. Baker I is within the expected range. Baker II is often monitored when the breast looks normal and symptoms are limited. Shorter follow-up intervals may be appropriate if firmness is changing. An operation is not automatically better than observation when the clinical burden is low.

Visible distortion at Baker III or pain with advanced firmness at Baker IV usually moves the discussion toward surgery. One option is capsulotomy, in which the tight capsule is released without removing all of it. Another is partial capsulectomy, removing the abnormal or strategically important portions. Total capsulectomy removes the capsule more completely when disease is extensive and the dissection is appropriate. The choice is not made from Baker grade alone; posterior adherence, rupture, calcification, tissue thickness, and bleeding risk matter.

Implant exchange is commonly considered because an old or damaged implant should not simply be returned to a revised pocket. The new implant is selected for the current tissue envelope rather than copied automatically from the first operation. In selected cases, changing the placement plane creates a new tissue interface. Pocket repair may be required if the fold or implant position is abnormal. Some patients choose implant removal without replacement, in which case deflation, sagging, and asymmetry should be discussed along with possible fat grafting or lift options.

If inflammation or infection makes immediate replacement unsuitable, removal and later reconstruction may be safer than a same-day exchange. Suspected rupture or late fluid changes the specimen-handling and diagnostic plan. A separate oncologic pathway is required when BIA-ALCL is suspected; routine contracture revision should not be described as equivalent to cancer surgery.

Revision can reduce firmness, pain, and distortion, but no operation guarantees that contracture will never return. Recurrence risk is addressed by removing or releasing the problematic capsule as appropriate, correcting the pocket, controlling bleeding, minimizing implant contact, and selecting an implant and plane for the present anatomy. Those measures change the conditions around the implant; they do not control every part of healing biology.

• •Observation with clinical and imaging follow-up for stable, mild findings.
• •Capsulotomy to release selected tight areas without removing the entire capsule.
• •Partial or total capsulectomy according to capsule condition and safe access.
• •Implant exchange, with a new size or surface chosen for current tissue.
• •Pocket repair or plane change when position, coverage, or scar behavior warrants it.
• •Implant removal, with or without later fat grafting, lift, or reimplantation.

The Korean source procedure guide lists an approximate operating time of one to two hours under general anesthesia, same-day discharge in typical cases, suture removal around seven to ten days, and return to ordinary daily activity in roughly one to two weeks. These are planning ranges, not commitments. Total capsule removal, rupture cleanup, plane change, pocket reconstruction, or treatment on both sides can make recovery longer or more uncomfortable.

Early swelling and asymmetry can obscure the result. Patients receive individualized instructions for wound care, support garments, sleep position, arm use, exercise, travel, and follow-up. A person doing desk work may resume sooner than someone whose job involves lifting. International travel timing should be agreed with the surgical team, including a plan for review before departure and access to care after returning home.

Bleeding, infection, seroma, altered sensation, scarring, asymmetry, implant malposition, tissue injury, rupture, and recurrent contracture are among the issues discussed during consent. Contact the clinic promptly for rapidly increasing swelling, worsening one-sided pain, fever, redness, drainage, shortness of breath, or other unexpected symptoms. Recovery and the final contour vary with the starting anatomy, extent of dissection, implant decision, and individual healing.

An international patient comparing Korea with care at home should compare the scope of surgery, not a headline package price. Capsular contracture revision can mean a limited release, partial capsulectomy, total capsulectomy, rupture cleanup, implant exchange, plane change, fold repair, or a combination. Anesthesia, imaging, pathology when indicated, implant choice, postoperative visits, and the complexity of a previously operated pocket also affect the cost structure.

That is why Umnagumo does not state one universal revision amount in this guide. An initial consultation quote is prepared after the team reviews the history, current symptoms, photographs, available ultrasound findings, implant information, and the likely capsule plan. The operative plan can still change if the capsule is more adherent, calcified, ruptured, or extensive than preoperative assessment suggested; the consultation should explain how that possibility is handled.

For travel planning, ask what the quote includes, how many in-person assessments are expected, when flying may be considered, where urgent care would be obtained after departure, and how remote follow-up works across time zones. Choosing a clinic in Gangnam that is dedicated exclusively to breast surgery may simplify continuity for a complex breast problem, but location and focus do not guarantee a result. The safer comparison is the clarity of diagnosis, the proposed capsule strategy, contingency planning, and follow-up responsibility.